Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study

Table 4 Factors associated with flares after vaccination (n = 2182) *

Variables	HR	95% CI
Diagnosis
Rheumatoid arthritis	ref
Psoriatic arthritis	1.29	0.96–1.72
Spondyloarthritis	0.83	0.58–1.18
Age	1.00	0.99–1.01
Female sex	1.04	0.81–1.34
Chinese race	1.07	0.83–1.37
Disease activity before vaccination
Remission	ref
Low disease activity	1.55	1.20–2.01
Moderate and high disease activity	1.98	1.43–2.74
COVID-19 vaccine type
Pfizer	ref
Moderna	1.38	1.03–1.86
Two vaccine doses before index visit	0.08	0.06–0.10

*A multivariable mixed effects Cox regression analysis was conducted to identify factors associated having a flare, while accounting for the clustering effect by Singapore hospital clusters. Patients who fulfilled the primary outcome (flared within 3 months from first vaccine dose) and who did not flare were included in the analysis
CI confidence interval, COVID-19 Coronavirus disease 2019, HR hazard ratio, PsA psoriatic arthritis, RA rheumatoid arthritis, SpA spondyloarthritis

ISSN: 2523-3106